Table 1.
Clinical and molecular characteristics of the patients enrolled in this study (N = 395)
| Parameter | Value |
|---|---|
| Age | Median 59.35 (range, 16–92) |
| Sex | 185/395 patients were female (46.8%) |
| 210/395 patients were male (53.2%) | |
| De novo AML | 307/372 patients (82.5%) |
| AML secondary to myelodysplastic syndrome | 43/372 patients (11.6%) |
| AML secondary to other myeloid neoplasms | 4/372 patients (1.1%) |
| Therapy-related AML | 18/372 patients (4.8%) |
| WBC (mean) | 28.140/mm3 (100–171.00/mm3) |
| WBC count greater than 30,000/mm3 | 46/154 patients (29.9%) |
| WBC count greater than 100,000/mm3 | 12/154 patients (7.8%) |
| European LeukemiaNet (ELN) low risk [37] | 35/352 patients (8.9%) |
| European LeukemiaNet (ELN) intermediate 1 risk [37] | 100/352 patients (28.4%) |
| European LeukemiaNet (ELN) intermediate 2 risk [37] | 80/352 patients (22.7%) |
| European LeukemiaNet (ELN) high risk [37] | 137/352 patients (38.9%) |
| Chemotherapy in induction | 251/308 patients (81.5%) |
| Gemtuzumab Ozagomicin was added | 42/251 patients (16.7%) |
| Complete remission | 153/251 patients (60.9%) |
| Hematopoietic stem cell transplant | 85/283 patients (30.0%) |
| Loss or a mutation of TP53 at diagnosis | 63/395 patients (15.9%) |
| Loss | 29/395 patients (7.3%) |
| Mutation | 53/324 patients (16.4%) |
| Internal tandem duplication in FLT3 | 42/298 patients (14.1%) |
| Tyrosine kinase domain mutation in FLT3 | 18/298 patients (6.0%) |
| Mutations in NPM1 gene | 50/286 patients (17.5%) |
| Mutations in IDH1 gene | 4/121 patients (3.3%) |
| Mutations in IDH2 gene | 11/135 patients (8.3%) |
| Mutations in DNMT3A gene | 7/38 patients (19.4%) |
| Mutations in CEBPA gene | 5/106 patients (4.7%) |
| Mutations in RUNX1 gene | 11/87 patients (12.6%) |
| Mutations in CBL gene | 2/91 patients (2.2%) |
| Mutations in NRAS gene | 10/95 patients (10.5%) |